Rashida A Ferrand
Rashida A Ferrand is an expert in Infectiology at Aga Khan University Hospital (Pakistan). As of October 2026, ScienceLeadR ranks Rashida A Ferrand in the top 1% of experts worldwide for Sexually Transmitted Diseases, HIV Infections and Immunologic Deficiency Syndromes. Rashida A Ferrand has authored 376 publications, the most recent in 2026, and is an investigator in 6 clinical trials, 2 of them ongoing. SLR score: 1,632 (community average: 125). How the SLR is computed.
LeadR Profile
Infectiology
Subspecialties: Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Organizations
Career arc: 2005 - 2026
Number : 376
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
Clinical Studies 6
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| An Adolescent Health and Wellbeing Check up Programme in Three African Cities (Y Check) NCT06090006 — depression, exercise, injections, oral health, research design, sexually transmitted diseases, malaria, hypertension, epilepsy, sexual behavior, circumcision, male, life style, immunization, healthy lifestyle, adolescent behavior, body mass index, hiv testing, safety, trichomonas infections, blood, eating, puberty, anemia, emergencies, pharmaceutical preparations, blood pressure, condoms, contraception, papilloma, adolescent development, hearing, contraceptives, oral, neisseria, diet, vaccination, employment, smartphone, adolescent, hiv, prehypertension, sexuality, viruses, health promotion, anxiety disorders, health facilities, folic acid, toothpastes, therapeutics, cities, diamines, overweight, history, sphygmomanometers, contraceptive agents, education, chlamydia, mental health, gonorrhea, suicide, human papillomavirus viruses, fluoride treatment | N/A | Recruiting | 2023 |
| DTG 3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to 15 Years Old NCT04337450 — pharmaceutical preparations, lamivudine, tablets, nucleosides, rna-directed dna polymerase, maintenance, aged, hiv, peptide hydrolases, protease inhibitors, hiv infections, reverse transcriptase inhibitors, infections, child, integrases, dolutegravir | Phase 2/Phase 3 | Active not recruiting | 2022 |
LeadR Networks
Main global connection map